[Iron overload and iron chelation therapy in transfusion-dependent patients]
- PMID: 18326327
[Iron overload and iron chelation therapy in transfusion-dependent patients]
Abstract
Many patients with bone marrow failure need repetitive transfusion of red blood cells and most of them finally suffer from organ dysfunction induced by excessively accumulated iron. The only way to treat iron overload caused by blood transfusion is iron chelation therapy. But most patients have not been treated sufficiently, because optimal administration of deferoxamine, the only iron chelator available in Japan, is difficult for many reasons. Recently, a novel oral iron chelator, deferasirox has been developed, and it is expected to improve chelation therapy in Japan in the near future. In this review, I will discuss the current and future status of iron overload and iron chelation therapy in transfusion-dependent patients. I will also introduce a proposed guideline for the diagnosis and treatment of iron overload in Japan.
Similar articles
-
Japanese epidemiological survey with consensus statement on Japanese guidelines for treatment of iron overload in bone marrow failure syndromes.Int J Hematol. 2008 Jul;88(1):30-35. doi: 10.1007/s12185-008-0119-y. Epub 2008 Jun 27. Int J Hematol. 2008. PMID: 18581199 Free PMC article. Review.
-
Iron-chelating therapy for transfusional iron overload.N Engl J Med. 2011 Jan 13;364(2):146-56. doi: 10.1056/NEJMct1004810. N Engl J Med. 2011. PMID: 21226580 Free PMC article. Review.
-
Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload.Expert Opin Pharmacother. 2008 Sep;9(13):2391-402. doi: 10.1517/14656566.9.13.2391. Expert Opin Pharmacother. 2008. PMID: 18710363 Review.
-
Iron chelation therapy for patients with sickle cell disease and iron overload.Am J Hematol. 2010 Oct;85(10):782-6. doi: 10.1002/ajh.21806. Am J Hematol. 2010. PMID: 20721892 No abstract available.
-
[Pathogenesis of transfusional iron overload and iron chelation therapy].Rinsho Ketsueki. 2009 Jul;50(7):527-31. Rinsho Ketsueki. 2009. PMID: 19638719 Review. Japanese. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources